CHEK1 and endometrial cancer: Takeuchi et al. [60] reported that VE-822 reduced the expression of p-CHK1 in HEC-1-B and HEC-6 endometrial cancer cell lines, and combined with DXR, CDDP, or IR, significantly enhanced tumor cell killing, confirming its chemo/radiotherapy sensitization effect.